| Wednesday, December 18, 2024 | Follicular Lymphoma: IHC Correlates of Molecular Genetic and Epigenetic Aspects | Dennis O’Malley |
| Wednesday, November 13, 2024 | Immunohistochemistry for Predictive Biomarkers in Lung Cancer | Stew Yang |
| Wednesday, October 16, 2024 | The Crucial Role of IHC in Papillary Breast Lesions | Megan Troxell |
| Wednesday, September 11, 2024 | Applications of IHC in Bone Tumor Pathology | Greg Charville |
| Wednesday, June 14, 2023 | Emerging Next-Generation Immunohistochemical Markers: Mainline Diagnostic Applications, A Couple Useful Tricks, and a Few Pitfalls | Andrew Bellizzi |
| Wednesday, May 24, 2023 | A Neoclassical Evaluation of Classical Hodgkin Lymphoma | Dennis O’Malley |
| Wednesday, April 12, 2023 | IHC in GYN Pathology | Matthew Quick,Anne Mills, Jaclyn Watkins, Brooke Howitt |
| Wednesday, March 8, 2023 | State of the Art and Science of Immunocytochemistry | Irena Srebotnik Kirbiš |
| Wednesday, February 15, 2023 | IHC Applications and New Developments in T-cell Lymphoma | Ahmet Dogan |
| Wednesday, January 18, 2023 | Diagnostic Applications of IHC in Thoracic Pathology | Rex Hung |
| Wednesday, December 21, 2022 | IHC in Oncologic Neuropathology | Melike Pekmezci |
| Wednesday, November 16, 2022 | Case-Based Presentation Highlighting Pearls and Perils of HER2 FISH | Hadi Yaziji |
| Wednesday, October 12, 2022 | Introducing IHC Analytic Calibration: theory and practice | Steve Bogen |
| Wednesday, September 14, 2022 | Low HER2: New Drugs Need a New Assay | David Rimm |
| Wednesday, June 15, 2022 | Solving the Puzzle of Aggressive B-cell Lymphomas | Dennis O’Malley |
| Wednesday, May 11, 2022 | The IHC Biomarker Ki67: Proliferation, Promise and Problems | Allen Gown |
| Wednesday, April 13, 2022 | Next-Generation Immunohistochemistry for Soft Tissue Tumors: Transforming Surgical Pathology Practice | Jason Hornick |
| Wednesday, March 16, 2022 | The Value of IHC in Melanocytic Tumor Pathology | Thomas Brenn |
| Wednesday, February 16, 2022 | Pan-Cancer Applications of p53 Immunohistochemistry | Andrew Bellizzi |
| Wednesday, January 12, 2022 | Diagnostic Immunohistochemistry in Breast Pathology | Megan Troxell |
| Wednesday, July 14, 2021 | Significance of Pathologist's Readout for IHC Biomarker Assays: Art or Science? | Emina Torlakovic |
| Wednesday, June 16, 2021 | Troubleshooting Diagnostic IHC Testing | Richard Cartun |
| Wednesday, May 26, 2021 | A Four Decade Sojourn Through Markers of Carcinomas of Unknown Primary | Allen Gown |
| Wednesday, April 14, 2021 | PD-L1 Testing Across Different Platforms and Different Purposes: the ABCs of Fit-for-purpose in IHC | Carol Cheung |
| Wednesday, March 17, 2021 | Ask the experts! | Megan Troxell, Andrew Bellizzi, Paul Swanson |
| Wednesday, February 17, 2021 | The Future of Immunohistochemistry | Paul Swanson |
| Wednesday, January 13, 2021 | High-Grade Neoplasms of Uncertain Lineage: Do’s and Don’ts of “Ancillary” Testing | Andrew Bellizzi |
| Wednesday, December 16, 2020 | 2020 Update on ER and PR Testing in Breast Cancer | Megan Troxell |
